Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5441593 | 1.00 | CYP1A2 (0.64) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL5443335 | 1.00 | CYP1A2 (0.64) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL5434321 | 1.00 | CYP1A2 (0.64) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL5441592 | 1.00 | CYP1A2 (0.64) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL5434325 | 1.00 | CYP1A2 (0.64) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL8337559 | 1.00 | CYP1A2 (0.64) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL5436210 | 1.00 | CYP1A2 (0.64) | CYP1A2USP2ALDH1A1LMNATSHR | |
| Hydrochloric Acid SCHEMBL5690730 | 0.98 | CYP1A2 (0.62) | CYP1A2USP2ALDH1A1LMNATSHR | |
| Hydrochloric Acid SCHEMBL5909676 | 0.98 | CYP1A2 (0.62) | CYP1A2USP2ALDH1A1LMNATSHR | |
| Hydrochloric Acid SCHEMBL5909675 | 0.98 | CYP1A2 (0.62) | CYP1A2USP2ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4681116-B2 | — | — | 2011-05-11 | — | — | JP | claimed |
| US-20110039875-A1 | PHARAMACEUTICAL COMPOSITIONS FOR TREATING CHRONIC PAIN AND PAIN ASSOCIATED WITH NEUROPATHY | TRINITY LABORATORIES, INC. | 2011-02-17 | — | — | US | claimed |
| EP-2184986-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATING CHRONIC PAIN AND PAIN ASSOCIATED WITH NEUROPATHY | Trinity Laboratories, Inc. (US) | 2010-05-19 | — | — | EP | claimed |
| EP-1009399-B1 | GABA ANALOGS TO PREVENT AND TREAT GASTROINTESTINAL DAMAGE | WARNER LAMBERT CO (US) | 2010-03-24 | — | — | EP | claimed |
| WO-2009021058-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATING CHRONIC PAIN AND PAIN ASSOCIATED WITH NEUROPATHY | TRINITY LABORTORIES, INC. (US) | 2009-02-12 | — | — | WO | claimed |
| US-7423169-B2 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | XENOPORT, INC. (US) | 2008-09-09 | — | — | US | claimed |
| US-7232924-B2 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | XENOPORT, INC. (US) | 2007-06-19 | — | — | US | claimed |
| JP-3884486-B2 | — | — | 2007-02-21 | — | — | JP | claimed |
| US-20060287250-A1 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | XENOPORT, INC. | 2006-12-21 | — | — | US | claimed |
| EP-1658098-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA2DELTA LIGAND AND AN OPIOID RECEPTOR ANTAGONIST FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| WO-2001042190-A1 | METHOD FOR THE STEREOSELECTIVE SYNTHESIS OF CYCLIC AMINO ACIDS | WARNER-LAMBERT COMPANY (US) | 2001-06-14 | — | — | WO | claimed |
| US-6127418-A | USING, E.G. PREGABALAN, GAGAPENTIN, FOR A PATIENT WHO IS OR WILL RECEIVE NSAID THERAPY OR ALCOHOL ABUSE THERAPY; INFLAMMATORY BOWEL DISORDER; IRRITABLE BOWEL SYNDROME; CROHN'S DISEASE, ILEITIS, ISCHEMIC BOWEL DISEASE | WARNER-LAMBERT COMPANY (US) | 2000-10-03 | — | — | US | claimed |
| EP-1032555-A1 | CYCLIC AMINO ACIDS AND DERIVATIVES THEREOF USEFUL AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2000-09-06 | — | — | EP | claimed |
| EP-1009399-A1 | GABA ANALOGS TO PREVENT AND TREAT GASTROINTESTINAL DAMAGE | WARNER-LAMBERT COMPANY LLC (US) | 2000-06-21 | — | — | EP | claimed |
| EP-0994704-A1 | USE OF GABA ANALOGS SUCH AS GABAPENTIN IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING INFLAMMATORY DISEASES | WARNER-LAMBERT COMPANY (US) | 2000-04-26 | — | — | EP | claimed |
| EP-0974351-A2 | Medicament for preventing and treating gastrointestinal damage | JOUVEINAL (FR) | 2000-01-26 | — | — | EP | claimed |
| WO-1999021824-A1 | CYCLIC AMINO ACIDS AND DERIVATIVES THEREOF USEFUL AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-05-06 | — | — | WO | claimed |
| WO-1999008671-A1 | GABA ANALOGS TO PREVENT AND TREAT GASTROINTESTINAL DAMAGE | WARNER-LAMBERT COMPANY (US) | 1999-02-25 | — | — | WO | claimed |
| WO-1999008670-A1 | GABA ANALOGS TO PREVENT AND TREAT GASTROINTESTINAL DAMAGE | GUGLIETTA, ANTONIO | 1999-02-25 | — | — | WO | claimed |
| WO-1998058641-A1 | USE OF GABA ANALOGS SUCH AS GABAPENTIN IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING INFLAMMATORY DISEASES | WARNER-LAMBERT COMPANY (US) | 1998-12-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287250-A1 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | GABRB1, GABRB3, GABBR1 | CYP1A2 1323/4885USP2 1225/4885ALDH1A1 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.